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S26 Journal of Thoracic Oncology Vol. 11 No. 2Sfor IA vs IB, p¼0.29). Patients with a high-risk PS
(>27) had a three-fold increased risk of distant
recurrence compared to patients with a low-risk PS
score. In stage I patients, the estimated risk of distant
recurrence for tumors with high-risk prognostic
scores was signiﬁcantly higher (36%, 95%CI 28%-
46%) than in low-risk PS tumors (15%, 95%CI 8%-
29%, p¼0.0005).
Conclusions: The prediction of risk of distant recur-
rence in resected lung adenocarcinoma patients can be
improved over that obtained by the current standard of
pathological stage by incorporating tumor expression of
proliferation markers (CCP score). Improved risk strati-
ﬁcation can help identify patients in need of additional
treatment and prioritize patients for trials of emerging
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Lung cancer is the second most common cancer type
and the leading cause of cancer-related death in both
men and women in the United States. Although recent
advances in genomic expression proﬁling of lung
cancer has provided more individualized treatment
based on target speciﬁc genetic alteration(s) in pa-
tients, there is a still high unmet medical need as
many important driver mutations remain undruggable
by conventional therapeutic approaches. Antisense
oligonucleotide (ASO) technology offers a novel ther-
apeutic modality to selectively target currently
undruggable pathways. We have recently demon-
strated that systemic delivery of unformulated next
generation (Gen 2.5) ASO targeting human STAT3
mRNA (STAT3-Rx/AZD9150) leads to robust phar-
macological activity in various preclinical animal
models of lung cancer. Importantly, STAT3-Rx/
AZD9150 displayed strong anti-tumor activity in pa-
tients with advanced treatment-refractory lymphoma
as well as non-small cell lung cancer (NSCLC) in
clinical trials*.
Although local delivery of ASOs has been proposed as
a means to treat various pulmonary diseases, ASO
pharmacology in lung tumors has not been previously
evaluated. In this study, we evaluated the activity of anantisense inhibitor (targeting MALAT1 gene) given by
different administration routes {by either a local (intra-
tracheally¼IT) or a systemic (subcutaneously¼SC) de-
livery} in orthotopic lung cancer xenograft models. For
this, human NSCLC A549 or H460 cells were injected to
nude mice via tail vein and 2 weeks later, the tumor-
bearing animals were treated with Gen 2.5 MALAT1 ASO
either IT (at 10 to 20 mg/kg, 3 times per week) or SC (at
25 to 50 mg/kg, 5 times per week) for 3 weeks. Re-
ductions in MALAT1 RNA levels in human tumor cells
and mouse lung were greater with local delivery at lower
doses compared to systemic delivery as assessed by
qRT-PCR or in-situ hybridization using species-speciﬁc
primers/probes (73% reduction at 20 mg/kg by IT
dosing vs 50.5% reduction at 50 mg/kg by SC dosing in
tumors; 72.5% vs 70% reduction in mouse lung at the
same dosing regimen). Moreover, local administration of
ASOs led to no notable increase in liver transaminase
levels compared to systemic administration. Pharmaco-
kinetic property-wise, the local administration showed
greater and more even accumulation of drug in both
tumor and lung tissues compared to the systemic route.
Taken together, these ﬁndings suggest that local
administration of Gen2.5 ASOs to lung malignancies
may be a promising alternative approach to systemic
delivery with greater potency and improved safety pro-
ﬁle, especially in inhibiting lung cancer targets which
cannot be tolerated when depleted systemically.
*Hong D et al. AZD9150, a Next-Generation Antisense Oligo-
nucleotide Inhibitor of STAT3 with Early Evidence of Clinical
Activity in Lymphoma and Lung Cancer. Sci. Transl. Med. 2015
(in press).
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Activating mutations of K-ras, which are found in
approximately 30% of non-small cell lung cancer
(NSCLC), are the most common genetic alterations
associated with tobacco exposure in lung cancer.
Unfortunately, pharmacologic attempts directly tar-
geting K-ras have thus far failed; clearly stating
the need for new strategies to bring clinical beneﬁts
to patients displaying such a molecular proﬁle.
Tumor-promoting inﬂammation is a cancer hallmark,
and it is now apparent that the cytokines and
growth factors released during inﬂammation inﬂuence
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lung cancer mouse model, CC-LR (CCSPCre/LSL-K-
rasG12D), we previously showed that K-ras mutant
lung tumors have intrinsic inﬂammatory characteris-
tics. This was associated with activation of NF-kB
pathway, release of inﬂammatory cytokines IL-6, and
IL-17A, and activation of the IL-6 responsive tran-
scription factor STAT3. We have further shown
that IL-6/STAT3 pathway, and IL-17 producing
CD4 helper T cells (Th17 cells) through their main
cytokine, IL-17A, play critical roles in promotion of
lung cancer in this model. Interleukin-22 (IL-22) is
another effecter molecule secreted by Th17 cells
which is highly expressed and produced in our K-ras
mutant mouse model. IL-22 is a unique cytokine in
the IL-10 family which seems to act exclusively on
nonhematopoietic cells, with basal IL-22R expression
in the epithelial cells and ﬁbroblast, and mostly sig-
nals through STAT3 pathway. Here we found that
genetic ablation of IL-22 in CC-LR mice (CC-LR/IL22-
KO mice) results in a signiﬁcant reduction in lung
surface tumor numbers by w54% (2.1-fold)
compared to age and sex matched control CC-LR mice.
Histopathological analysis of H&E stained lung sec-
tions also conﬁrmed reduction in number and size of
tumors and less adenomatous lesions in CC-LR/IL22-
KO mice compared to CC-LR mice. Immunohisto-
chemical staining of lung tissues with speciﬁc
markers, Ki-67, CD-31 and pSTAT3 demonstrated
signiﬁcantly lower tumor cell proliferation, angio-
genesis and STAT3 activation in CC-LR/IL22-KO mice.
IL-22 ablation also reduced the numbers of inﬂam-
matory cells in bronchoalveolar lavage ﬂuid,
decreased the expression of pro-tumor inﬂammatory
cytokines such as IL-6, IL-17 and TNFa, and increased
expression of anti-tumor inﬂammatory cytokines such
as IFNg. Recent studies have shown an association
between IL-22 and stem-cell like properties in colon
cancer. In lung cancer, populations expressing
NANOG, SOX2, Oct4 and/or aldehyde dehydrogenase
activity are enriched with stemness properties.
Interestingly, in CC-LR/IL22-KO mice we found sig-
niﬁcant reduction in expression of NANOG, SOX2 and
Oct4. Thus, we conclude that IL-22 promotes K-ras
mutant lung tumorigenesis by inducing a pro-tumor
inﬂammatory microenvironment with proliferative
and angiogenic properties as well as protecting
stemness characteristic in epithelial/tumor cells.
Therefore, we propose pharmacological targeting
of IL-22 as a potential therapeutic strategy in com-
bination with conventional cytotoxic therapy, immune
check point blockade, or other targeted therapies
(e.g. MEK inhibition) for lung cancer patients with
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Purpose: To investigate serial changes of tumor hypoxia
in response to ablative radiation treatment by using
various clinical and pre-clinical methods in order to
propose an optimal fractionation schedule for stereo-
tactic ablative radiotherapy (SABR).
Methods and Materials: Syngeneic Lewis lung carci-
nomas were grown either orthotopically or subcuta-
neously in C57BL/6 mice and were irradiated with a
single dose of 15 Gy to mimic SABR used in the clinic.
Serial [18F]-misonidazole (F-MISO) positron emission
tomography (PET) imaging, pimonidazole FACS ana-
lyses, hypoxia-responsive element (HRE)-driven
bioluminescence, and Hoechst 33342 perfusion were
performed before irradiation (d-1), at 6 hours (d0),
2 (d2), and 6 days (d6) after irradiation for both
subcutaneous and orthotopic lung tumors. For F-MISO,
the tumor-to-background activity ratio (TBR) was
calculated.
Results: We observed that hypoxic signals were too
low to quantitate for orthotopic tumors by F-MISO
PET and HRE-driven bioluminescence imaging. In
subcutaneous tumors we observed that TBR values
were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ±
0.334 at d2, and 2.13 ± 0.385 at d6, indicating that
tumor hypoxia decreased after irradiation and
returned to the pretreatment levels and then slightly
decreased by 2 and 6 days post-radiation, respectively.
Pimonidazole analysis also revealed similar patterns.
By using Hoechst 33342 vascular perfusion dye and
CD31 co-immunostaining, we found that there was a
rapid and transient vascular collapse, which may have
resulted in poor intratumoral perfusion of F-MISO PET
tracer and pimonidazole at d0 hence leading to the
decreased hypoxic signals.
Conclusions: We found tumor hypoxia levels to be
returned to the pretreatment levels by 2 days after
irradiation, hence supporting the use of current frac-
tionation intervals of SABR being given at least 2 days.
Our results also indicate that SABR may produce a rapid
and transient vascular collapse in tumors.
